Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:EVAX NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.37-5.1%$0.57$0.29▼$1.65$30.42M2.08510,238 shs1.52 million shsEVAXEvaxion A/S$2.75-9.8%$2.73$1.20▼$17.75$4.27M0.1378,983 shs178,206 shsPMVPPMV Pharmaceuticals$1.40-2.8%$1.35$0.81▼$1.82$76.31M1.52304,026 shs1.15 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-5.14%-9.75%-18.33%-51.64%-63.25%EVAXEvaxion A/S-9.84%-15.38%-0.72%+13.17%-81.73%PMVPPMV Pharmaceuticals-2.78%-5.41%-1.41%+61.66%-11.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSDClearside Biomedical2.4591 of 5 stars4.13.00.00.02.90.00.0EVAXEvaxion A/S2.4461 of 5 stars3.52.00.00.02.71.70.6PMVPPMV Pharmaceuticals3.102 of 5 stars3.53.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 2.17Hold$4.201,042.86% UpsideEVAXEvaxion A/S 3.00Buy$10.00263.64% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50292.86% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, PMVP, and CLSD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$1.66M17.38N/AN/A($0.62) per share-0.59EVAXEvaxion A/S$3.34M1.15N/AN/A$4.44 per share0.62PMVPPMV PharmaceuticalsN/AN/AN/AN/A$2.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$0.37N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.32N/AN/AN/A-316.03%-319.52%-63.56%10/30/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)Latest EVAX, PMVP, and CLSD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EVAXEvaxion A/S-$0.50-$0.76-$0.26-$0.76N/A$0.04 million8/8/2025Q2 2025CLSDClearside Biomedical-$0.12-$0.06+$0.06-$0.06$0.50 million$0.49 million8/7/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39-$0.41-$0.02-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87EVAXEvaxion A/S1.733.423.42PMVPPMV PharmaceuticalsN/A12.5212.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%EVAXEvaxion A/S11.04%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%EVAXEvaxion A/S41.64%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3078.51 million73.25 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataPMVPPMV Pharmaceuticals5052.99 million48.98 millionOptionableEVAX, PMVP, and CLSD HeadlinesRecent News About These CompaniesPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 7, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 7, 2025 | globenewswire.comPMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comRobert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockJuly 4, 2025 | insidertrades.comPmv Pharmaceuticals Inc (PMVP) - Investing.comJuly 3, 2025 | investing.comPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comQPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comAHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 21, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, PMVP, and CLSD Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.37 -0.02 (-5.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.14%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Evaxion A/S NASDAQ:EVAX$2.75 -0.30 (-9.84%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.80 +0.04 (+1.64%) As of 08/29/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.PMV Pharmaceuticals NASDAQ:PMVP$1.40 -0.04 (-2.78%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.71%) As of 08/29/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
